Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares saw unusually-high trading volume on Friday . Approximately 144,279 shares changed hands during mid-day trading, a decline of 0% from the previous session’s volume of 144,843 shares.The stock last traded at $8.01 and had previously closed at $7.79.

KPTI has been the subject of a number of research reports. Robert W. Baird initiated coverage on Karyopharm Therapeutics in a research note on Monday, June 27th. They issued an “outperform” rating and a $16.00 target price for the company. Canaccord Genuity set a $20.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Saturday, August 6th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Finally, HC Wainwright initiated coverage on Karyopharm Therapeutics in a research note on Thursday. They issued a “buy” rating and a $15.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $17.25.

The stock’s market capitalization is $290.79 million. The firm has a 50 day moving average price of $7.20 and a 200-day moving average price of $7.82.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.84) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08. Analysts predict that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current fiscal year.

In other news, major shareholder Ltd Chione sold 46,122 shares of the company’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $9.73, for a total transaction of $448,767.06. Following the completion of the transaction, the insider now owns 8,772,060 shares of the company’s stock, valued at $85,352,143.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent SEC filing.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.